Home / Market News / $DYN

$DYN news and market catalysts

The 19 most recent market catalysts affecting $DYN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

19 catalysts 7 high impact 5 bullish 10 bearish Biotechnology
Nov 5, 2026 Corporate Catalyst Neutral Impact 85
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics announced its Q3 2026 financial results, showing a larger net loss driven by increased operational costs related to its clinical programs. The most impactful disc…
Oct 28, 2026 Corporate Catalyst Bearish Impact 55
Oppenheimer Downgrades Dyne Therapeutics to Perform
Oppenheimer has downgraded Dyne Therapeutics (DYN) from an 'Outperform' rating to 'Perform' and established a price target of $15. This action signals a less optimistic view from a…
Sep 29, 2026 Corporate Catalyst Bullish Impact 75
Dyne Therapeutics Continues To Expect Topline Data In Q1 2027 From The Achieve REC, With A Primary Endpoint Of Change From Baseline In vHOT At 6 Months, Intended To Support A Potential Submission For U.S. Accelerated Approval In Q3 2027
The announcement of topline data in Q1 2027 for Dyne Therapeutics' ACHIEVE REC trial is a major future catalyst for the company. The primary endpoint, change from baseline in vHOT …
Sep 29, 2026 Corporate Catalyst Bullish Impact 75
Dyne Therapeutics Announces Additional One-Year Clinical Data From Phase 1/2 ACHIEVE Trial
Dyne Therapeutics released additional one-year clinical data from its Phase 1/2 ACHIEVE trial for z-basivarsen, a drug targeting Myotonic Dystrophy Type 1 (DM1). The data showed fu…
Sep 9, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $36
Morgan Stanley analyst Michael Ulz maintained an 'Overweight' rating on Dyne Therapeutics (DYN), signaling a belief that the stock will outperform the broader market. However, the …
Sep 9, 2026 Corporate Catalyst Bearish Impact 55
RBC Capital Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $30
RBC Capital's analyst Luca Issi maintained an 'Outperform' rating on Dyne Therapeutics, suggesting continued confidence in the company's long-term prospects. However, the price tar…
Sep 9, 2026 Corporate Catalyst Bearish Impact 55
Baird Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $26
Baird analyst Brian Skorney maintained an 'Outperform' rating on Dyne Therapeutics (DYN) but lowered the price target from $30 to $26. This action signals that while the analyst st…
Sep 8, 2026 Corporate Catalyst Bearish Impact 85
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Novartis announced that its Phase 3 HARBOR study for del-desiran in Myotonic Dystrophy Type 1 (DM1) failed to show statistically significant improvement on its primary endpoint. Th…
Jul 31, 2026 Corporate Catalyst Bearish Impact 55
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley's analyst Michael Ulz maintained an 'Overweight' rating on Dyne Therapeutics, signaling a positive long-term outlook for the company. However, the price target was s…
Jul 30, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
RBC Capital analyst Luca Issi maintained an 'Outperform' rating on Dyne Therapeutics and raised the price target from $30 to $35. This action signals a strengthened positive outloo…
Jul 29, 2026 Corporate Catalyst Bearish Impact 92
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Dyne Therapeutics (DYN) announced its Q2 earnings per share, reporting a loss of $(1.08), which significantly missed the analyst consensus estimate of $(0.75) by 44%. This is a cri…
Jul 28, 2026 Corporate Catalyst Bullish Impact 85
Dyne Therapeutics Announces FDA Clearance Of IND Application For DYNE-302, Enabling Phase 1 Trial In FSHD
The FDA's clearance of the IND application for DYNE-302 is a critical de-risking event for Dyne Therapeutics, enabling the initiation of a Phase 1 trial for Facioscapulohumeral Mus…
Jul 23, 2026 Corporate Catalyst Neutral Impact 55
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt has initiated coverage on Dyne Therapeutics (DYN) with an Overweight rating. This is a positive development for Dyne Therapeutics as it signa…
Jul 22, 2026 Corporate Catalyst Bearish Impact 85
Dyne Therapeutics shares are trading lower after the company announced the pricing of its $376 million offering of 18.3 million shares at $20.50 per share.
The headline indicates a significant corporate catalyst: a secondary stock offering. Dyne Therapeutics (DYN) is directly impacted as the increased share count dilutes existing shar…
Jul 22, 2026 Corporate Catalyst Neutral Impact 75
Reported Earlier, Dyne Therapeutics Prices Upsized $375M Public Offering Of 18.3M Common Shares At $20.50 Per Share
This headline signifies a significant capital raise for Dyne Therapeutics, providing essential funding for its research and development activities. The 'upsized' nature suggests st…
Jul 22, 2026 Corporate Catalyst Bearish Impact 75
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
Dyne Therapeutics priced an upsized public offering of 18.3 million shares at $20.50, generating $375.2 million in gross proceeds. This move is a common strategy for clinical-stage…
Jul 21, 2026 Corporate Catalyst Bearish Impact 85
Dyne Therapeutics shares are trading lower after the company announced a $300 million offering.
The announcement of a $300 million stock offering by Dyne Therapeutics is a significant corporate catalyst, directly impacting the company's share price negatively due to dilution …
Jul 21, 2026 Corporate Catalyst Neutral Impact 75
Dyne Therapeutics Announces $300M Public Stock Offering
This $300M public stock offering by Dyne Therapeutics is a significant corporate catalyst primarily for DYN. While it provides essential funding for their R&D pipeline, it will lea…
Jul 20, 2026 Corporate Catalyst Bullish Impact 85
Dyne Therapeutics' Biologics License Application For Zeleciment Rostudirsen Got FDA Acceptance For Review To Treat Duchenne Muscular Dystrophy
Dyne Therapeutics announced a major positive development with the FDA's acceptance of its Biologics License Application (BLA) for zeleciment rostudirsen, a treatment for Duchenne m…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.